Defra / APHA will provide an update on the current situation, followed by a presentation about BTV by Peter Mertens, Professor of Virology, University of Nottingham, and Christopher Sanders, Research Fellow in Veterinary Entomology from the Pirbright Institute.
If can't attend, you can register to be sent a recording afterwards.
This is the first of a series of bluetooth update webinars which will be held fortnightly on Wednesdays at 6pm.
https://ahdb.org.uk/events/bluetongue-virus-technical-webinar
The Registry’s dataset now contains the details of 1,319 canine cruciate surgical procedures, compared with 735 reported in 2023.
The report contains 3 years of data provided by 138 UK-based vets and their clients, and reports on cruciate surgery outcomes on dogs from all stages of life – from 3 months to 18 years.
The report provides a breakdown of the clinical outcomes of different surgical techniques, patient demographics, use of antibiotics, and more.
Some of the main findings in this year’s annual report were:
Mark Morton, Clinical Lead for the Registry, said: “It has been fantastic to see the CCR go from strength to strength this year with contributions from owners and vets across the country.
"Evaluating what we do and sharing this information with owners is really important.
"There is now sufficient data in the registry that vets can use the reporting functionality to see how they compare to anonymous data from the registry as whole.
"This allows everyone to look at where we can improve what we do to enhance outcomes for our patients.”
Steve Butterworth, veterinary surgeon at Weighbridge Referral Service, Swansea, and CCR contributor, said: “To better understand the long-term outcomes for different breeds of dog using differing surgical techniques we need the power of numbers and this will only be achieved by pooling our resources.
"The CCR offers the veterinary profession an opportunity to do this.
Any veterinary surgeon performing cruciate surgery in the UK can get involved in the CCR by signing up and logging surgical cases.
All data submitted by summer 2025 will be anonymised and become part of the next report in late 2025.
ccr.rcvsknowledge.org/annualreport
An online quiz by the RCVS has shown that veterinary surgeons generally have good understanding of the Guide to Professional Conduct, but that misconceptions about the role of the college are rife.
Around 850 people completed the quiz since it was launched in November 2009, with veterinary surgeons accounting for 70% of those that took part. The average score was 20 out of 25
Despite the high average score, there were several questions which a very significant number of people got wrong. The worst related to the role of the RCVS: 76% of people wrongly thought that the College's remit included negligence, whilst 66% believed that the RCVS could not consider criminal convictions (it can).
Nearly half of those taking part were not aware that the standard of proof to which the RCVS Disciplinary Committee must be satisfied is 'so as to be sure' - the same as for a criminal court.
Other questions poorly answered related to 24-hour cover, delegation to paraprofessionals, consent and ownership of records. The RCVS Communications Board will consider how to improve communications in these areas.
In terms of age, the highest scoring age-band was 51-60, achieving an average of 20.5 right answers; the lowest was '30 or under', at 18.7. However, this is not backed up by distribution of complaints to the RCVS, where only 27% of complaints relate to those who have less than ten years' post-qualification experience, although this group makes up 43% of registrations.
The results indicate that there is no significant difference between the genders in terms of Guide knowledge, at 19.54 right answers for men and 19.46 for women. Meanwhile, only 34% of complaints to the RCVS are made about women, while they account for 51% of the Register. However, as women tend to dominate the younger end of the profession, this statistic may be linked to the fact that a greater percentage of complaints relate to older individuals, more likely to be men.
Lizzie Lockett, RCVS Head of Communications said: "We hoped the quiz would offer a light-hearted way for vets - and others - to review their knowledge of the Guide, which can be a dry read, and have been pleased with the response.
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
A special interest group has been established for vets, veterinary nurses and chartered physiotherapists interested in the rehabilitation of diseased and injured animals. 'Physiovet UK' aims to provide practical training in the field of veterinary rehabilitation and pain management.
The group's inaugural CPD meeting takes place on Wednesday 20th May this year in Cardiff and will be led by specialist in small animal surgery (orthopedics) Steve Butterworth and veterinary rehabilitation specialist Lowri Davies. Sponsored by Hill's Pet Nutrition and Merial Animal Health, the meeting will cost £80 for members or £100 for non-members (ex VAT) for the day long event. Membership of the group costs £50.
Lowri Davies, a founder member of Physiovet said: "At this first meeting, the focus is on helping to develop a protocol for diagnosis and management strategies for conditions of the hock, shoulder and lumbosacral cases. Practitioners will recognise that these are commonly occurring conditions that are often managed conservatively but treatment need not stop with a prescription of 'rest'. We will be describing a range of active interventions that build strength, flexibility and general fitness appropriate to lame animals to help restore function and mobility."
For a downloadable registration form for the event, to join as a member or for further information about the group visit http://www.physiovet.co.uk/. Places at the meeting can also be booked by calling 01626 867614 or by contacting kathrin@linhayvet.co.uk.
A new veterinary charity is offering veterinary surgeons, nurses and others in the profession the chance to get fit and raise money for Hounds for Heroes, SPANA and the Pet Blood Bank later this year.
The Vet Charity Challenge (VCC) is looking for teams to take part in a one-day event, involving a series of physical tasks and puzzle-solving challenges along the way, so it requires a bit of brain as well as brawn. The course will feature walking / running, cycling and kayaking and anyone can take part at whatever fitness level.
As well as raising money for the charities, organisers say it will be a fun way to build up camaraderie among your colleagues outside of the work environment and also a local PR opportunity for your practice or business to enhance your community profile.
The event is expecting to raise in excess of £30,000 for charity, but organisers stress that it will need the support of and participation by the veterinary profession to ensure it is a success.
The challenge will take place on Saturday 15th September 2012 at the Royal Agricultural College, Cirencester and all details may be found on http://www.vetcharitychallenge.co.uk/. Alternatively, ring 01727 859259 for further information. The VCC says an early commitment to take part is essential and the fine detail of training can be worked out later. The VCC will provide training guidelines and help you and your team prepare itself.
The Vet Charity Challenge is sponsored by BCF Technology, Kruuse UK Ltd and Vets 2 and is supported by the VPMA, Mojo Consultancy and JCA Media Group.
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
Researchers at the Royal Veterinary College have officially launched a new Feline Diabetic Remission Clinic in the Queen Mother Hospital for Animals in Hertfordshire, to investigate the optimum methods to achieve good control, and ultimately diabetic remission, in diabetic cats.
Led by Dr Stijn Niessen, the team at the new clinic will offer diabetic cats optimum management, while at the same time gathering information to enhance current scientific understanding of the best treatment for diabetic cats.
Feline diabetes mellitus is a costly, chronic disease which can significantly decrease the quality of life of both cat owners and their pets. However, a proportion of diabetic cats can achieve diabetic remission and no longer require insulin therapy, which is increasingly considered the ultimate goal in treating diabetic cats. According to the RVC, early evidence suggests that good, early blood glucose control increases remission rates in diabetic cats. However, there is little evidence about which treatment protocol offers the best blood glucose control and chance of remission.Stijn said: "Our mission is to investigate the best method of achieving good blood glucose control, and diabetic remission, in diabetic cats. The clinic also aims to identify predictors of diabetic remission, which will help veterinarians advise their clients on the chance of their cat achieving diabetic remission in the future."
He added: "Interestingly, most cats seem to suffer from a similar type of diabetes as most humans. We always suspected cats to be extremely wise, but isn't it interesting to know that they also might hold the answer to many questions we have about the human disease!"
The clinic is currently recruiting cats that have had diabetes for less than 4 months' duration for a clinical trial, examining the effect of new insulins on blood glucose control and remission rate.
Enrolled cats will qualify for full underlying disease assessment at the referral hospital, several re-examination appointments, 12 months of prescription diabetic food, and 6 months of insulin therapy - all at no cost to owners.
For more information on the trial or the work of the clinic, contact Feline Diabetic Remission Clinic: telephone: 01707 666 605 or email: fdrc@rvc.ac.uk
MSD Animal Health's equine division has launched a new series of materials to support its Keeping Britain's Horses Healthy Campaign.
For veterinary practices, there's a Vet Reception Pack designed to help receptionists educate owners why they should vaccinate and the benefits of preventive healthcare.
For yards, there are posters giving guidance and advice on prevention of Infectious Respiratory Disease and the steps which should be taken to control a potential outbreak. They can be tailor made for an individual yard.
Peter Young, MSD Animal Health Equine Business Manager said: "Our first wave of support materials focused very much on equine vets and owners - helping raise awareness of the importance of preventive healthcare and driving owners towards vets for advice. This phase of materials helps support yard owners and receptionists, aiming to fill some of those communications gaps where advice and guidelines on individual horse's vaccination requirements and yard protocols can play a vital role in preventing the spread of disease and controlling outbreaks."
Keeping Britain's Horses Healthy is a national campaign to educate horse owners on endemic infectious disease, vaccination, herd immunity and the importance of preventative healthcare. It includes a range of educational materials for veterinary surgeries and direct to owners. The campaign is supported by a national PR, advertising and social media programme, together with a dedicated website www.healthyhorses.co.uk. The website, aimed at driving owners back to their veterinary practices, includes a vet finder, exclusively for equine practices, and healthcare information.
For full details of the launch programme, talk to your account manager, call 01908 685685 or visit www.healthyhorses.co.uk.
Four separate studies are included in the collection, reporting novel risk factors for the disease, identifying key differences between EGS and botulism (questioning the hypothesis that EGS is caused by neurotoxins from Clostridium botulinum), reporting a novel diagnostic technique and showing the value of monitoring weight loss to help predict whether individual horses with chronic EGS are likely to survive.
The publishers say that despite more than 100 years of research, supported predominantly by the The Moredun Foundation Equine Grass Sickness Fund (www.grasssickness.org.uk), the cause of EGS remains unknown. Since it almost exclusively affects grazing horses, a pasture derived neurotoxin is implicated. EGS causes gut paralysis as a result of damage to parts of the nervous system that control involuntary functions. Acute and sub-acute EGS is invariably fatal while around 55% of chronic cases can survive and return to a useful working life. The UK has the highest incidence of EGS in the world; indeed it is estimated that the disease kills between 1 and 2% of horses in the United Kingdom annually. Cases are more common in spring.
In terms of risk factors, the study ‘Equine grass sickness in Scotland: A case-control study of environmental geochemical risk factors’ suggests that the high incidence of the disease in Eastern Scotland may be partly associated with the particular composition of macro and trace elements in the soil in the fields on which horses graze. Further work is required to determine whether interventions to alter concentrations of particular elements in soil could potentially reduce the risk of EGS.1
A second study identified key differences between EGS and botulism, which questions the currently favoured hypothesis that EGS is caused by neurotoxins from Clostridium botulinum, a bacterium which commonly inhabits soil. The study ‘Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya’ suggests that EGS is unlikely to be caused by neurotoxins from this bacterium and concludes that further investigation of an alternative cause for EGS is needed.2
While the majority of horses with EGS can be readily diagnosed by experienced veterinary surgeons, some cases present a diagnostic challenge. Indeed the only way to definitively diagnose the disease in a live horse is to demonstrate the characteristic degeneration of nerves within biopsies of the intestine. Unfortunately these biopsies can only be collected by performing abdominal surgery under general anaesthesia. In the study ‘Neuronal chromatolysis in the subgemmal plexus of gustatory papillae in horses with grass sickness’ characteristic degeneration of nerves was identified in small biopsies collected from tongues of EGS horses during post mortem examination. Examination of these biopsies accurately differentiated control horses from EGS cases. While further validation of this technique is required, it could potentially provide a relatively non-invasive method of confirming the diagnosis in a live horse.3
While around 55% of horses with chronic EGS survive, objective criteria for predicting survival of these cases are currently lacking. The study ‘Bodyweight change aids prediction of survival in chronic equine grass sickness’ reported that non-survivors had greater rate and magnitude of bodyweight loss than survivors. Survival prediction curves were published to allow veterinary surgeons and horse owners to use body weight data to help determine whether an individual horse with chronic EGS was likely to survive or die.4
Professor Bruce McGorum, Head of the Equine Section at the Royal (Dick) School of Veterinary Studies & Roslin Institute in Edinburgh, has been leading much of the research. He said: "Given that our recent research suggests that EGS is unlikely to be caused by neurotoxins from Clostridium botulinum we are now moving on to determine whether EGS is caused by ingestion of mycotoxins produced by pasture fungi. We are very pleased that The Horse Trust (www.horsetrust.org.uk) has provided funding for this three-year investigation."
Professor Celia Marr, Editor of the Equine Veterinary Journal said: “While the cause of equine grass sickness continues to evade us, these papers present an optimistic step in the right direction for the eventual prevention of this dreadful disease. It is only with the support of the Moredun Foundation Equine Grass Sickness Fund and more recently that of The Horse Trust that our world-leading veterinary researchers are able to continue to unravel the mystery.”
The EVJ equine grass sickness collection can be downloaded at http://bit.ly/2dC7Drr
References
Annual renewal fees for veterinary surgeons will remain at the same level as in 2021: £364 for UK-practising members, £182 for members practising outside the UK and £60 for non-practising members.
The removal of the alternative fee payment arrangements means there will no longer be the option to pay in instalments and the fee needs to be paid in full by the usual deadline of 1 April.
RCVS Treasurer Niall Connell said: “We understand that many veterinary surgeons and veterinary nurses will have been impacted financially over the last couple of years, and we appreciate that this has been a very difficult time for the professions.
"We are pleased that we are able to keep fees static for a second year running, whilst maintaining a strong programme of strategic projects that help to set, uphold and advance standards within the professions.”
Sanofi-aventis and Merck & Co., Inc. announced today that Sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck's Animal Health business.
The new joint venture will be equally-owned by Merck and Sanofi-aventis. The formation of this new joint venture is subject to execution of final agreements, antitrust review in the United States, Europe and other countries, and other customary closing conditions. The completion of the transaction is expected to occur in approximately the next 12 months.
Richard T. Clark, Merck Chairman, President and Chief Executive Officer said: "Merck has been in the animal health business for well over six decades and through this new joint venture, we will bolster our diverse portfolio and create a new global competitor poised for growth.
"This new joint venture delivers on Merck's commitment to customer focus by creating one of the broadest portfolios of animal health products and services in pharmaceuticals and biologics for millions of customers who include farmers, veterinarians and pet owners. The planned joint venture will have an attractive geographical network of global technology and expertise to provide health solutions based on customers' needs, which often vary regionally."
The worldwide animal health market reached $19 billion in 2008. Products for companion animals accounted for 40 percent of total sales while products for production animals accounted for the remaining 60 percent of total sales. This market is expected to grow at around 5 percent per year over the next 5 years, driven by a growing demand for animal proteins, as well as a strong consumer needs for companion animal health care.
The companies said that both Merial and Intervet/Schering-Plough will continue to operate independently until the closing of the transaction.
The RCVS Disciplinary Committee has dismissed a case against a Nottinghamshire veterinary surgeon, having found not proven the charge that he had caused, allowed or failed to prevent a potential breach of the Rules of Racing of the Greyhound Board of Great Britain (GBGB).
During the re-scheduled, three-day hearing, the Committee heard that Dr Gary Samuel was on duty on 10 October 2009 as the GBGB licensed track veterinary surgeon at Nottingham Greyhound Stadium. When the trainer came to collect her dog for the race, she discovered a biscuit in his kennel in the paddock area, in potential contravention of the rules of the GBGB, which do not allow greyhounds access to any food, drink or other substance after weighing in, prior to a race. She reported this discovery to the paddock steward. The dog was withdrawn from the race, so there was no prospect of prize money. The trainer, despite her unblemished record, was put at risk of disciplinary action by the GBGB, which could have resulted in the loss of her training licence and livelihood. Following the events of 10 October, the GBGB held a disciplinary hearing, at which Dr Samuel was disqualified indefinitely from holding a GBGB licence and fined £2,500, and the matter was referred to the College.
The RCVS Disciplinary Committee confirmed that it should not be bound by the GBGB decision, and that the charges laid against Dr Samuel must be resolved on the basis of the evidence before it. Both Counsel for Dr Samuel and the College urged the Committee to have close regard of CCTV footage from 10 October, which showed Kennel 21 where the dog had been placed and the biscuit found. From evidence given by the paddock steward and the trainer, the Committee accepted that the kennel was clean when the dog entered at 5.30pm, so the biscuit must have been introduced between 5.30pm and 9pm, when the trainer collected him for the race.
The footage available to the Committee from Nottingham Race Track was only four-and-a-half minutes long. The Committee was concerned that there were almost three-and-a-half hours of footage that it had not been shown and that, in addition, witnesses were not able to state that they had viewed the remainder of the footage. In those circumstances, the Committee considered that the footage available must be of the best quality to allow it to reach a sure conclusion as to what exactly Dr Samuel may have been doing in his position close to Kennel 21. From the quality of the footage available, the Committee was not able to be sure.
Speaking on behalf of the Disciplinary Committee, Vice-Chairman Professor Sheila Crispin said: "The fact remains that the Committee cannot be sure that the Respondent caused the biscuit to enter Kennel 21, [so] finds the charge against the Respondent not proved."
Dr Samuel therefore remains on the RCVS Register and is entitled to practise.
Dorwest Herbs has launched its annual 'Dorwest Say Relax' fireworks phobia campaign, which includes free promotional packs for practices.
The promotional packs, which contain a poster, leaflets, flashing badges and a 'Dorwest Say Relax' t-shirt, being given free to the first 100 practices that request a product box (containing licensed Scullcap & Valerian Tablets and Organic Valerian Compound at a discounted price) from the company.
In addition, Dorwest is running a seemingly popular consumer facebook competition to find the most relaxed dog in the nation, the winner of which will be sent on a pet-friendly luxury weekend break.
Finally, the company is writing a blog written from the perspective of Merlin, the dog used in its logo - http://merlintakescontrol.wordpress.com - though quite who is going to read it, or why, is slightly beyond me.
Zoetis Business Consulting has announced the launch of Profitsolver, a software tool designed to boost practice profits.
The software has already been rolled out in the US, where Zoetis says that it has delivered an average of £103,000 extra profit to veterinary practices within a year.
Profitsolver uses the practice's actual data - not benchmarks or accepted norms - to enable the practice to manage costs, set prices and gain return on investments. By using an activity-based costing model and using a variety of data such as practice costs, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profitsolver calculates the correct pricing to both cover costs and deliver a predetermined profit margin.
Zoetis says that Profitsolver helps practices to understand how the overall practice profit is being generated. For instance, for price sensitive procedures such as vaccination, the practice can match their prices with the competition, but maintain their profit margin by increasing the price for other clinical services.
Nick Steele, national consulting manager at Zoetis said: "Veterinary practices have no standard method for pricing their services and they are often unable to determine which services make money and which don't. This hampers the practice's ability to accurately value the business and, as a result, profit levels tend to be low for many practices. Profitsolver can turn this situation around and already has a very successful track record in the US."
Zoetis piloted the UK version of Profitsolver with John Goulding at St Georges Veterinary Group. He said: "By and large the veterinary profession still relies on the mark-up of medicines where profits are concerned. Even practices that have made a concerted effort to move away from this type of pricing structure are still making their money from the sale of medicines rather than from vets' fees. For years I have wanted to know exactly how to price our services and this new Profitsolver software does just that.
"Most costs have an element of staff time, an element of fixed assets or equipment and an element of disposable items. Profitsolver takes all of these into account, adds the predetermined profit margin and produces an accurate pricing structure for each procedure undertaken within the practice.
"It's important to take the time at the start to put accurate data in from the practice's latest set of accounts and the Zoetis business consultant will guide practices through this to make the initial set up as easy as possible. For instance, for major pieces of equipment such as X-ray machines, you have to work out how many times a year you are likely to use them.
"By using Profitsolver, we worked out that if we do exactly the same amount of work as last year we can increase our bottom line by at least £200,000 for our 18 vet practice. Since last November, when we installed Profitsolver, we have completely changed our pricing structure moving away from focusing on medicines and the size of the animal to rethink how we charge our clinical care.
"An unexpected benefit is that Profitsolver has made me much more confident about the prices we charge to clients as it is all broken down, so we can see exactly how the invoice is made up. I would be at a loss without it now."
For more information about Profitsolver, contact your Zoetis account manager.
Ceva Animal Health has highlighted a new study which revealed that the use of the opioid buprenorphine, the active ingredient in Vetergesic, before equine elective general anaesthesia and surgery resulted in better post-operative analgesia than butorphanol, without causing further physiological disruption than is normally expected of general anaesthesia in horses.
The prospective, randomised and blinded multicentre study, conducted by Dr Polly Taylor VetMB MA PhD DVA DipECVAA MRCA MRCVS, an RCVS Specialist in Veterinary Anaesthesia, compared the degree of post-operative pain and physiological variables in horses following premedication with either buprenorphine or butorphanol in a general clinical setting. The study included 89 healthy adult horses from six UK equine veterinary clinics admitted for routine elective surgical procedures.
Ceva says that butorphanol is often used in equine procedures due to familiarity and its value for enhancing alpha2-induced sedation, but that it is probably the least effective opioid as an analgesic. There is also a common perception that butorphanol has less impact on locomotor stimulation and depression of intestinal motility than other opioids. This is likely to have contributed to the almost exclusive use of NSAIDs to manage pain in the post-operative period.
To view the full study, visit http://onlinelibrary.wiley.com/doi/10.1111/evj.12442/abstract. For details on Ceva's analgesic product range, email analgesics-group@ceva.com or call 01494 781510.
BCF Technology has launched the portable 9020HF Orange x-ray generator from Eco Ray.
BCF says the 9020HF is ideal for equine and large animal applications because it is is just marginally heavier than the 8016HF generator, but more powerful, allowing it to achieve excellent images of regions such as the stifle and spine.
The new BCF Clinical Development Manager and in-house vet Kimberly Palgrave said: "This new generator really fills the gap in the range and is an ideal balance between weight and power. It is also bright orange so impossible to miss when tidying the kit away in the yard."
BCF is also the sole official distributor in the UK and Ireland for Eco Ray generators.
To see the full range of X-ray generators and other X-ray and ultrasound equipment available from BCF visit http://www.bcftechnology.com/ or call +44 (0)1506 460023.
Dechra Veterinary Products is offering CPD sessions as podcasts for the first time, as part of a new series of presentations on canine hyperadrenocorticism.
The Cushing's Challenge series, which will also be available as webcasts with supporting notes, is designed to challenge vets to update their knowledge on the syndrome.
There will be six presentations released on the company's online learning resource, The Dechra Academy, starting this month.
Dechra Veterinary Products Brand Manager, Craig Sankey said: "Although Cushing's is a common canine endocrinopathy, it can be challenging to diagnose and can mimic non-adrenal disorders. Test results can also sometimes be inconclusive which is why we've developed this series of CPD sessions to support veterinary professionals who want to update their knowledge.
"The Cushing's Challenge series will be the first time Dechra has used podcasts to deliver CPD, which can be downloaded and listened to on any MP3 player. They can also be viewed on a PC or tablet as a webcast with each of the presentations varying in length, from around 12 to 25 minutes long. By offering the presentations in both of these formats, we are able to offer flexible support to help busy veterinary professionals with CPD.
"The first episodes will focus on pathophysiology, clinical signs and routine lab tests with successive presentations released in the coming weeks. The next two in the series will cover diagnostic tests and then differentiation tests."
CPD certificates will be available at the end of the series via email.
The free-of-charge CPD is accompanied by client support materials for practices as part of Dechra's new Vetoryl campaign.
The Cushing's Challenge CPD is available at www.dechra.co.uk/academy,
MSD Animal Health has reintroduced Zanil, the flukicide drench for cattle and sheep.
Based on the active ingredient oxyclozanide, MSD says Zanil is highly effective against the adult fluke responsible for chronic disease and - significantly for dairy farmers - is licensed for use in young, pregnant and lactating animals, with a 72-hour milk withhold period where milk is produced for human consumption.
MSD Animal Health veterinary advisor Matt Haslam said: "The latest independent data1 confirms that fluke is on the increase in UK cattle and sheep. The fluke problem is longstanding, but is being exacerbated by recent wet summer and autumn periods that have created ideal conditions for this parasite to proliferate and infect grazing livestock.
"Chronic liver fluke causes serious economic losses for livestock farmers. In dairy herds, for example, there will be a negative impact on fertility and milk production where cows are affected.
"It is important that farmers have access to the best treatment options given the size of the threat and the scale of potential losses. Zanil is used widely and effectively in Ireland in the control of fluke problems, and there is no known resistance to the active ingredient oxyclozanide. With its re-introduction into the country, we believe Zanil is unique as a flukicide-only treatment that is licensed for use in lactation and in the dry period for the treatment of adult fluke in dairy cows."
Zanil is an oral drench with POM-VPS authorisation, available from both animal health suppliers and veterinary practices. Dosage rate is 3ml per 10kg bodyweight in cattle, up to a maximum of 105ml, and 4.5ml per 10kg bodyweight in sheep, up to a maximum of 20ml.
Reference
See DEFRA emerging threats reports in sheep and cattle, Q1 2013: www.defra.gov.uk/ahvla-en/files/pub-survrep-sr0113.pdf
The Animal Health Trust is appealing to veterinary surgeons and nurses to encourage clients who keep their horses on premises that have been affected by Equine Grass Sickness to sign up to the second year of its nationwide EGS vaccine trial.
Equine Grass Sickness (EGS) occurs predominantly in Europe, with Britain experiencing the highest incidence worldwide. In 2014, 59 cases of EGS were reported through the EGS Surveillance Scheme, but it is likely that this represents only a fraction of cases occurring annually throughout Britain.
Almost all cases of EGS occur in horses with access to grazing. The AHT says there is growing scientific evidence to suggest that the disease may be caused by the bacterium Clostridium botulinum type C, commonly found within soil and capable of producing neurotoxins to which horses are particularly sensitive. EGS occurs when a combination of risk factors trigger the production of these toxins within the horse's intestinal tract, causing damage to the nervous system and paralysis of the gut.
As similar equine diseases such as tetanus and botulism can be prevented by vaccination, it is theoretically possible that a vaccine could prevent EGS. To this end the AHT, in collaboration with the Universities of Edinburgh, Liverpool and Surrey launched the EGS field vaccine trial in 2014 in order to establish whether a vaccine could indeed be effective in reducing the risk of the disease. The trial is funded by a number of sources including Neogen Corporation; Animal Welfare Foundation; Horserace Betting Levy Board; Racing Foundation; Moredun Foundation Equine Grass Sickness Fund; Hong Kong Jockey Club; The British Horse Society and the EB Moller Charitable Trust.
Now entering its second year, the EGS vaccine trial involves enrolled horses and ponies receiving either a course of the C. botulinum type C toxoid vaccine or an inactive placebo, as well as an annual booster. The incidence of EGS is monitored throughout the trial to determine the efficacy of the vaccine, and enrolled horses and ponies are closely monitored through regular follow-ups for the duration of the trial.
With 60% of EGS cases occurring during April - June, the highest risk season for EGS is fast approaching. The AHT is appealing to owners who keep their horses on premises that have had at least one case of EGS in the past three years to enrol their horse in the vaccine trial and provide an invaluable contribution to this pioneering research prior to these high risk months. Veterinary practices with clients who fit this description are asked to help the recruitment process by encouraging suitable cases to sign up to the trial.
Dr Jo Ireland, the AHT's Equine Grass Sickness Research Co-ordinator, said: "We have been delighted with the overwhelmingly positive response to the EGS vaccine trial and many owners have welcomed the chance to be a part of such important research. We don't want any eligible horse owners to miss out on the opportunity to contribute towards a potential breakthrough in the prevention of EGS, so we are encouraging more owners to enrol their horses on the trial this year."
To find out more about the vaccine trial or how clients can enrol horses and ponies, visit the AHT's dedicated EGS website www.equinegrasssickness.co.uk or email equinegrasssickness@aht.org.uk.
It is hoped the findings, which were unveiled at the House of Commons yesterday, will enable the welfare priorities of the UK’s 800,000 horses to be addressed.
This is the first time welfare organisations, breeders, the equine industry and the veterinary profession have come together to agree on a strategy to best improve the welfare of horses in the UK.
The equine welfare study found the welfare needs of many horses are not currently being met and the report has highlighted four welfare priorities.
Dr Siobhan Mullan, Research Fellow in Animal Welfare Science, Ethics and Law at the University of Bristol and one of the report’s authors, said: "Bringing together the views of people associated with horses in England and Wales has provided an overview of horse welfare, from the day-to-day concerns of equine caregivers to identifying four priority challenges to equine welfare.
"This research has also identified how equine welfare can be improved, by addressing both the priority challenges, and a wider set of industry and horse-based needs."
Roly Owers, World Horse Welfare Chief Executive, added: "This research report provides a vital insight to the UK’s equine sector, mapping out the welfare landscape from a wide range of sector experts and stakeholders.
"In order for World Horse Welfare and others to most effectively address the welfare challenges facing UK equines, we need to better understand today’s welfare priorities and this research will provide a valuable guide to help in driving the focus of our educational initiatives and resources over the next few years.”
The priority welfare challenges and solutions outlined in the report are:
Unresolved stress/pain behaviourProblems associated with unresolved stress/pain behaviour affect large numbers of horses, often for long durations with variable severity of suffering caused to individual horses.
More academic research is needed to fully understand the links between behaviour, stress and pain, and objective measures of stress and pain in horses should be developed. Vets, riding instructors, the Pony Club, riding clubs and the equine press have a role in educating horse caregivers about signs of stress and pain and the appropriate responses. Academics and experts also have a role in tackling this issue through evaluating the effectiveness of intervention programmes.
Inappropriate nutritionOverfeeding and obesity are the main welfare problems associated with nutrition and affect large numbers of horses, often for a long time with varying severity of suffering.
Vets have a key role in tackling the problems associated with inappropriate nutrition. A consistent approach by all vets is needed, to prevent horse owners choosing vets that don’t challenge owners about their horses’ nutrition. Feed companies can also play an important role in tackling this issue, although many feed companies already offer appropriate nutrition for a range of horses and exercise situations. Better owner education, based on existing good research, would ensure the right nutritional choices are made for individual horses.
Inappropriate stabling /turnoutWelfare of horses is compromised when the amount of time spent at pasture/stabled does not meet their individual needs, when they are kept in social isolation or when they are exposed to unsuitable grazing conditions. Welfare problems associated with incorrect stabling/turnout affect large numbers of horses for a long time with variable levels of suffering.
Although all horse owners make choices relating to the amount and type of stabling and turnout experienced by their horses, livery yard owners could play a role in addressing this issue. For example, by encouraging different approaches to management, including group housing and the use of all-weather turnout facilities. Strengthening legislation is another possible way for improvement but a ‘one size fits all’ approach would be inappropriate. For example, for some horses, turn out to pasture may not always be suitable.
Delayed deathHorses may be kept alive inappropriately resulting in firstly, prolonging welfare problems, such as continued suffering of a horse in pain. This affects relatively large numbers of horses, for short periods of time with the severity of suffering often being severe. Secondly, an increased risk of suffering, for example where horses are unwanted by their owners, become low value and subsequently aren’t cared for well.
One way for improvement could be by putting pressure on the EU to make changes to the passport regulations. In particular, legislation changes that would enable horses who had received medications, including Phenylbutazone, to be slaughtered to enter the human food chain after a six month withdrawal period. In addition, challenging negative attitudes of horse owners towards timely euthanasia is important.
The research, undertaken over a four year period, was to understand the welfare status of horses in England and Wales, identify priority welfare issues and explore horse owner and industry experts’ perceptions of these issues.
Stakeholders from across the equine industry contributed to the research: from vets to farriers and welfare charities to governing body representatives, participants represented a wide-reaching cross section of horse care roles and responsibilities.
The WSAVA is calling on veterinary surgeons around the world and anyone with an interest in veterinary – and human – medicine to sign the petition to ensure access to ketamine in the face of lobbying by some countries, principally China, to have it put under international scheduling.
According to the WSAVA, proposals for international control stem from the misconception that ketamine is merely a 'recreational drug.' The WSAVA says this is inaccurate and devalues its huge contribution to human and animal medicine.
Dr Walt Ingwersen, WSAVA President Elect and Member of the WSAVA’s Global Pain Council, said: "In 2015, the WHO Expert Committee on Drug Dependence (ECDD) stated that the abuse of ketamine does not cause a global public health threat and that control would limit access for those using it as an anaesthetic. This view was confirmed at a meeting of the UN Commission on Narcotic Drugs in March 2016, helped by strong support view from the global medical and veterinary communities. However, China has repeated its view that ketamine should fall under international scheduling and we have no doubt that it will raise the issue again. This mean the risk to ketamine remains."
He added: "Ketamine is a safe anaesthetic which can be used without oxygen, ventilators, electricity and the support systems required for other products, making it the only anaesthetic suitable for both medical and veterinary use in lower and middle income countries. If developing countries were denied access to it, which would be the effect of international scheduling, the effects on veterinary medicine, human health and animal welfare would be devastating."
Dr Ganga de Silva, President of the Society of Companion Animal Practitioners of Sri Lanka, said: "Sri Lanka is a poor country with an underdeveloped veterinary profession. If ketamine was not available, in my opinion, all surgeries would have to cease as almost all of the veterinarians in the country rely on it for anaesthesia. The result would be suffering for animals and it would also seriously impact our ability to control rabies as we would not be able to carry out spay and neuter programs on stray dogs."
Dr Nancy Shaffran CVT, VTS(ECC), President of the International Veterinary Academy of Pain Management, said: “In addition to its use as an anaesthetic agent, ketamine is a critical medication used in the pain management in animals. The mechanism of action of ketamine (NMDA receptor antagonism) delivered as a Constant Rate Infusion has been well established to be effective in the prevention and correction of severe neuropathic pain and spinal cord wind-up. The loss of ketamine in veterinary practice would result in the needless suffering of many patients and we strongly oppose this action. We are very grateful for WSAVA’s efforts to keep ketamine available for our patients."
Dr Walt Ingwersen added: "Ketamine is also used in human medicine as it has a particular value for use 'in the field' - for instance, in treating trauma patients, those with traffic and sporting injuries or affected by natural disasters and conflict. Taking these factors together, it is clear that ketamine is an essential medicine and we are determined to ensure that it remains freely available. We are continuing to harness our global veterinary community to highlight the importance of ketamine because this is a battle our patients can’t afford us to lose. We ask all those agreeing with to sign our petition and help our collective voice grow."
The petition is here: http://chn.ge/1RFSou6.
The WSAVA’s Global Pain Council has produced a range of tools and resources, including an infographic, to support its ketamine campaign. They can be accessed here: http://www.wsava.org/educational/global-pain-council
The 15 minute video (see below) is hosted by Chris Dixon, veterinary ophthalmologist and director at Veterinary Vision Ophthalmic Referrals, who discusses things to consider when examining a patient with an ocular disorder. He offers practical advice on how to perform an ocular examination, including tips on how to use an ophthalmoscope effectively, examining the ocular structures including the front eye, distant direct examination, indirect examination and close direct examination.
Chris said: "This series of videos aims to help vets learn how to perform the fundamental techniques of ophthalmic examination, hopefully enabling them to spot potentially degenerative conditions earlier. The second video in particular delves into practical tips that vets can use within practice. The videos have been created in partnership with Bayer as part of their ongoing commitment to training, and aim to help ensure that chronic conditions, such as keratoconjunctivitis sicca (KCS), or dry eye, are diagnosed and treated early."
The veterinary practice waiting room display materials are designed to help practices educate dog owners on the signs and management of Dry Eye in the hope that the condition may be diagnosed and treated earlier and to emphasise the importance of ongoing treatment and management.
Hannah Watts, Group Product Manager at Bayer said: "It is important that dog owners with a predisposed breed are aware that their pet may be at risk of developing Dry Eye and are aware of the symptoms. Annual testing in at risk breeds for Dry Eye is recommended to help reach an early diagnosis and optimise the chances of a successful treatment outcome."
The Dry Eye practice display materials are available to order via the Bayer Vet Centre www.vetcentre.bayer.co.uk. Alternatively, ask your Bayer rep for more details.
fVtqNMj35c8
The investment is being made to increase the speed at which concerns are either closed or referred, ensure that the process meets its service standards and reduce stress for the public and profession.
The decision to increase investment in the process was made by the College’s Operational Board in response to a steady increase in the number of concerns being investigated. The College forecasts that it will receive in excess of 1,000 concerns raised about the professional conduct of veterinary surgeons and veterinary nurses this year.
The RCVS developed a simplified, three-stage concerns process in 2014 which included the introduction of targets for cases to be either closed or referred at each stage. In order to ensure that these targets can be met, the College will now be hiring five paralegals to assist the existing five case managers.
Eleanor Ferguson, Acting Registrar, said: "Currently we are only closing or referring just over half of concerns we receive at stage 1 (case examiner stage) within our four month target. In order for the system to run more smoothly we will be investing in extra staff to help clear the backlog and ensure that these targets are met going forward.
"Similarly, in order to deal with the increase in the number of cases being referred to Preliminary Investigation Committee (stage 2), we will be increasing the frequency of these committee meetings from one to two per month.
"It is important to add that this investment is not just about dealing with concerns more quickly but is also about quality of service and having more staff on hand will ensure that this quality is maintained in terms of how we communicate with complainants and members of the profession. Speeding up the process will reduce the stress and anxiety felt by all involved."
More details about the College’s concerns investigation process and its different stages can be found at www.rcvs.org.uk/concerns
Genitrix has launched a scheme to help vet practices generate revenue through increasing sales of its canine mobility product, C2Collaplex. The scheme offers a money-back guarantee if clients and practices don’t see clear benefits from using C2Collaplex on dogs with mobility problems within a month.
In order to validate the scheme, clients are asked to complete a simple mobility score sheet and return it to the practice one month from the date of their original consultation. If both vet and client agree that C2Collaplex has made no difference, the practice will refund the client and Genitrix will forward on a replacement pack of C2Collaplex.
C2Collaplex, designed to promote the continuation of normal joint function in ageing and less mobile dogs, contains a range of nutritional substances, including Glucosamine HCl, Chronodroitin Sulphate, Vitamin C and Manganese, which help to support the musculo-skeletal system.
In addition, it contains purified Type II collagen which is the major protein of the cartilage in the joints. C2Collaplex is the only veterinary product to provide this protein in a purified form. According to Genitrix, it works by helping to switch off adverse processes and keeps cartilage normal.
In a retrospective study of 100 dogs presenting to practice with mobility problems, C2Collaplex was given as the only supportive agent and over 80% of veterinary surgeons and owners perceived a benefit from its use.
Commenting on the launch of ‘C2Collaplex Money Back Guarantee Scheme,’ Rob Watkins, Marketing Director of Genitrix, said: “The C2Collaplex Money Back Guarantee Scheme offers a win/win. It gives pet owners a well-priced, next generation product, which will help their dog. For the practice, it helps to build a strong revenue stream, with the guarantee of a refund if it fails to help an individual patient.”
For further information on participating, practices should contact Genitrix on 01403 786345.